| Haemodynamic definitions and updated clinical classification of pulmonary hypertension |
401 |
| Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019 |
250 |
| Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives |
111 |
| Exhaled air dispersion during high-flow nasal cannula therapy versus CPAP via different masks |
109 |
| Risk stratification and medical therapy of pulmonary arterial hypertension |
106 |
| 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS) |
82 |
| Pulmonary hypertension due to left heart disease |
73 |
| Paediatric pulmonary arterial hypertension: updates on definition, classification, diagnostics and management |
61 |
| Chronic thromboembolic pulmonary hypertension |
59 |
| A potential therapeutic role for angiotensin-converting enzyme 2 in human pulmonary arterial hypertension |
58 |
| Pulmonary hypertension in chronic lung disease and hypoxia |
57 |
| Diagnosis of pulmonary hypertension |
56 |
| ERS statement on respiratory muscle testing at rest and during exercise |
53 |
| Pathophysiology of the right ventricle and of the pulmonary circulation in pulmonary hypertension: an update |
45 |
| Genetics and genomics of pulmonary arterial hypertension |
44 |
| Laboratory-confirmed respiratory infections as triggers for acute myocardial infarction and stroke: a self-controlled case series analysis of national linked datasets from Scotland |
43 |
| Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report |
39 |
| Predicting EGFR mutation status in lung adenocarcinoma on computed tomography image using deep learning |
36 |
| Omalizumab effectiveness in patients with severe allergic asthma according to blood eosinophil count: the STELLAIR study |
35 |
| Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma |
35 |
| What's in a name? That which we call IPF, by any other name would act the same |
35 |
| The effect of gefapixant, a P2X3 antagonist, on cough reflex sensitivity: a randomised placebo-controlled study |
35 |
| European Respiratory Society guidelines on long-term home non-invasive ventilation for management of COPD |
35 |
| Electronic cigarettes: a task force report from the European Respiratory Society |
33 |
| E-cigarette vapour enhances pneumococcal adherence to airway epithelial cells |
33 |
| Proliferating SPP1/MERTK-expressing macrophages in idiopathic pulmonary fibrosis |
32 |
| Inhaled corticosteroids in COPD: friend or foe? |
31 |
| Phenotypes of organ involvement in sarcoidosis |
31 |
| The global prevalence of latent tuberculosis: a systematic review and meta-analysis |
30 |
| Clinical trial design and new therapies for pulmonary arterial hypertension |
30 |
| Post-approval upper airway stimulation predictors of treatment effectiveness in the ADHERE registry |
30 |
| Macitentan in pulmonary hypertension due to left ventricular dysfunction |
29 |
| ERS/EACTS statement on the management of malignant pleural effusions |
28 |
| The Global Initiative for Asthma (GINA): 25 years later |
27 |
| Air pollution, lung function and COPD: results from the population-based UK Biobank study |
27 |
| Triple therapy versus single and dual long-acting bronchodilator therapy in COPD: a systematic review and meta-analysis |
26 |
| Challenges and perspectives in obstructive sleep apnoea Report by an ad hoc working group of the Sleep Disordered Breathing Group of the European Respiratory Society and the European Sleep Research Society |
26 |
| Reducing tuberculosis transmission: a consensus document from the World Health Organization Regional Office for Europe |
24 |
| A randomised clinical trial of feedback on inhaler adherence and technique in patients with severe uncontrolled asthma |
24 |
| Treatable traits: a new paradigm for 21st century management of chronic airway diseases: Treatable Traits Down Under International Workshop report |
23 |
| Consequences of long-term oral corticosteroid therapy and its side-effects in severe asthma in adults: a focused review of the impact data in the literature |
23 |
| Electronic cigarette use in youths: a position statement of the Forum of International Respiratory Societies |
23 |
| Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases |
23 |
| Nonadherence in the era of severe asthma biologics and thermoplasty |
22 |
| Investigating unilateral pleural effusions: the role of cytology |
22 |
| Living with breathlessness: a systematic literature review and qualitative synthesis |
21 |
| The importance of patient perspectives in pulmonary hypertension |
21 |
| Optimising experimental research in respiratory diseases: an ERS statement |
20 |
| The incidence of tuberculosis among adolescents and young adults: a global estimate |
19 |
| Reductions in dead space ventilation with nasal high flow depend on physiological dead space volume: metabolic hood measurements during sleep in patients with COPD and controls |
19 |
